Prof. MD. Çağlayan Geredeli

Education and Specialization

• 1994 Selçuk University Faculty of Medicine
  
• 2012 NEU Meram Faculty of Medicine, Medical Oncology Specialist
  
• 2018 Associate Professor of Medical Oncology
  

Experience

• 1994–1995 Kütahya Gediz State Hospital
  
• 1995–1999 Dicle University Faculty of Medicine Hospital, Internal Medicine
  
• 2000–2001 Şırnak Silopi State Hospital, Internal Medicine Specialist and Chief Physician
  
• 2002–2003 Ankara Polatlı SSK Hospital, Internal Medicine Specialist
  
• 2004–2007 Ankara Polatlı Hayrettin Ekmen State Hospital, Internal Medicine Specialist and Chief Physician
  
• 2008–2009 Ankara Polatlı Duatepe State Hospital, Internal Medicine Specialist and Deputy Chief Physician
  
• 2010–2012 Necmettin Erbakan University Meram Faculty of Medicine, Department of Medical Oncology
  
• 2013–2014 Konya Training and Research Hospital, Medical Oncology Specialist
  
• 2015–2017 Istanbul Okmeydanı Training and Research Hospital, Medical Oncology Specialist
  
• 2018–2021 Istanbul Okmeydanı Training and Research Hospital, Medical Oncology Instructor
  
• 2022–2023 Istanbul Prof. Dr. Cemil Taşcıoğlu City Hospital, Medical Oncology Training Supervisor
  

Courses and Certifications

• 2010 Boğaziçi University Good Clinical Practice Certificate
  

Professional Memberships

• Member of the Turkish Society of Medical Oncology
  
• Member of the Association for Oncological Clinical Research
  
• Member of the Marmara Oncology Association
  

Articles Published in International Peer-Reviewed Journals

1. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study Ayse Irem Yasin, Sabin Goktas Aydin, Bilge Sümbül, Lokman Koral, Melih Şimşek, Çağlayan Geredeli, Akın Öztürk, Perihan Perkin, Derya Demirtaş, Engin Erdemoglu
2. Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer. Tumour Biology: The Journal of the International Society
GEREDELI ÇAĞLAYAN, ARTAC MEHMET, YILDIRIM MAHMUT SELMAN, INAL ALI, DEDE ISA, GULER TUNC, BORUBAN MELIH CEM, KORAL LOKMAN, KARAAĞAÇ MUSTAFA, ZAMANI AYSEGUL, ALTINOK TAMER, ARIBAŞ OLGUN KADIR, BOZCUK HAKAN, DEMIRKAZIK AHMET
3. FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer. World Journal of Surgical Oncology, 16(1), 67
GEREDELI ÇAĞLAYAN, YAŞAR Nurgül
4. The prognostic significance of the 18F-fluorodeoxyglucose positron emission tomography/computed tomography in early-stage non-small cell lung cancer. Journal of Cancer Research and Therapeutics

GEREDELI ÇAĞLAYAN, ARTAC MEHMET, KOCAK İSMAIL, KORAL LOKMAN, SAKIN ABDULLAH, ALTINOK TAMER, KAYA BUGRA, KARAAĞAÇ MUSTAFA

5. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology). Oncology, 83(3), 141–150

KAPLAN MUHAMMET ALİ, IŞIKDOĞAN ABDURRAHMAN, KOCA DOĞAN, KÜÇÜKÖNER MEHMET, GÜMÜŞAY ÖZGE, YILDIZ RAMAZAN, DAYAN A, DEMIR LÜTFIYE, GEREDELI ÇAĞLAYAN, KOÇER MURAT, ARSLAN ÜLKÜ, INAL ALİ, ÜNAL OLÇUN ÜMİT, MERT AG, BILICI MEHMET, ÖZKAN METİN, ELKIRAN EMİN

6. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: A study by the Anatolian Society of Medical Oncology. Breast Cancer

KAPLAN MUHAMMET ALİ, IŞIKDOĞAN ABDURRAHMAN, KOCA DOĞAN, KÜÇÜKÖNER MEHMET, GÜMÜŞAY ÖZGE, YILDIZ RAMAZAN, DAYAN A, DEMIR LÜTFIYE, GEREDELI ÇAĞLAYAN, KOÇER MURAT, ARSLAN ÜLKÜ, INAL ALİ, AKMAN TÜLAY, COŞKUN UĞUR, ŞENER N, İNANÇ MEVLÜDE, ELKIRAN EMİN TAMER, ÖZDEMİR NURİYE, DURNALI AG, SÜNER ALİ, ALICI S, TARHAN

7. Efficacy and Safety of Erlotinib in Previously Treated Advanced Non–Small Cell Lung Cancer. International Journal of Hematology and Oncology, 23(1), 1–6.

Karaca Halit, GEREDELI ÇAĞLAYAN, KAPLAN MUHAMMET ALİ, DEMİRCİ UMUT, ALICI SÜLEYMAN, ARTAC MEHMET, IŞIKDOĞAN ABDURRAHMAN, BENEKLI MUSTAFA, BALAKAN OZAN, Arpaci Erkan, Budakoğlu Burçin, UNCU DOĞAN, GÜLER TUNÇ, BERK VELİ, ÖZKAN METİN

8. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective multicenter analysis.

INAL ALI, KOŞ FT, ALGIN EFGAN, YILDIZ RAMAZAN, DİKİLİTAŞ MUSTAFA, ÜNEK İLKAY TUĞBA, ÇOLAK D, ELKIRAN EMİN TAMER, HELVACI KAAN, GEREDELI ÇAĞLAYAN, DANE FAYSAL, BALAKAN OZAN, KAPLAN MUHAMMET ALİ, DURNALI AG, HARPUTLUOĞLU HAKAN, GÖKSEL ÖZTÜRK GAMZE, ÖZDEMİR

9. Childhood, adolescents, and young adults (≤25 years) colorectal cancer: study of the Anatolian Society of Medical Oncology. Journal of Pediatric Hematology/Oncology, 35(2), 83–89.

KAPLAN MUHAMMET ALİ, IŞIKDOĞAN ABDURRAHMAN, GÜMÜŞ MAHMUT, ARSLAN ÜLKÜ, GEREDELI ÇAĞLAYAN, ÖZDEMİR NURİYE, KOCA DOĞAN, DANE FAYSAL, SÜNER ALİ, ELKIRAN EMİN TAMER, KÜÇÜKÖNER MEHMET, Şeker Metin, HELVACI KAAN, GÜLER TUNÇ, UNCU DOĞAN, INAL ALİ, YILDIZ

10. Endocrine therapy alone vs. chemotherapy plus endocrine therapy for the treatment of elderly patients with endocrine-responsive and node-positive breast cancer: a retrospective multicenter analysis. Journal of BUON

INAL ALİ, AKMAN TÜLAY, YAMAN S, DEMİR ÖZTÜRK S, GEREDELI ÇAĞLAYAN, BİLİCİ MEHMET, İNANÇ MEVLÜDE, HARPUTLUOĞLU HAKAN, DEMİRCİ UMUT, BALAKAN OZAN, H. YEŞİL ÇİNKİR, ALICI SÜLEYMAN, UYSAL SÖNMEZ ÖZLEM, GÖKSEL ÖZTÜRK GAMZE, GÖKÖZ DOĞU GAMZE, ÜNAL OLÇUN ÜMİT, TAMÖZLÜ TA, BÜYÜKBERBER SÜLEYMAN, BORUBAN MELİH CEM, IŞIKDOĞAN AB.

11. Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective multicenter analysis

INAL ALİ, Kodaz Hilmi, Odabaşı Hatice, OCAK DURAN AYŞE, Şeker Metin, İNANÇ MEVLÜDE, ELKIRAN EMİN TAMER, GÜNAYDIN YUSUF, Menekşe Serkan, Öztürk Topçu Türkan, URAKÇI ZUHAT, Taştekin Didem, BİLİCİ MEHMET, Cihan Şener, GEREDELI ÇAĞLAYAN, SEZER EMEL, UNCU DOĞAN, ARPACI ERKAN

12. Is lymph node ratio a prognostic factor for survival in elderly node-positive breast cancer patients? The Anatolian Society of Medical Oncology. Annali Italiani di Chirurgia, 84(2), 143–148.

INAL ALİ, AKMAN TÜLAY, YAMAN S, ÖZTÜRK SC, GEREDELI ÇAĞLAYAN, BİLİCİ MEHMET, İNANÇ MEVLÜDE, HARPUTLUOĞLU HAKAN, DEMİRCİ UMUT, SÜNER ALİ, Çınkır HY, ALICI SÜLEYMAN, ÇOLAK D, Sönmez OU, GÖKSEL ÖZTÜRK GAMZE, DOĞU GG, ENGİN HÜSEYİN, ÜNAL OLÇUN ÜMİT

13. Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective multicenter analysis. Contemporary Oncology

İnal Ali, Kos FT, Algın E, Ünek İT, Çolak D, DANE FAYSAL, GEREDELI ÇAĞLAYAN, IŞIKDOĞAN ABDURRAHMAN, Yıldız Ramazan, BERK VELİ

14. Pathologic and clinical characteristics of elderly patients with breast cancer: a retrospective multicenter analysis. International Surgery, 99(1), 2–7

INAL ALİ, AKMAN TÜLAY, YAMAN S, ÖZTÜRK SC, GEREDELI ÇAĞLAYAN, BİLİCİ MEHMET, İNANÇ MEVLÜDE, HARPUTLUOĞLU HAKAN, DEMİRCİ UMUT, BALAKAN OZAN, ÇANKIR HY, ALICI SÜLEYMAN, ÇOLAK D, SÖNMEZ OU, GÖKSEL ÖZTÜRK GAMZE, DOĞU GG, ENGİN HÜSEYİN, ÜNAL OLÇUN

15. Fulvestrant efficacy in artificial menopausal hormone receptor–positive and HER2-negative metastatic breast cancer patients under 50 years old. International Journal

GEREDELI ÇAĞLAYAN, YAŞAR Nurgül

16. Rationale for Palliative Gastrectomy and Metastasectomy in Metastatic Gastric Cancer. International Journal of Current Research and Review, 10(7), 6–

Sakin Abdullah, Tambaş Makbule, YAŞAR Nurgül, GEREDELI ÇAĞLAYAN, Seçmeler Şaban, Demir Cumhur, Alemdar Ali, GÜVEN HAKAN, Cihan Şener

17. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective multicenter analysis. Journal of BUON, 17, 102–105.

INAL ALİ, KOŞ FT, ALGIN EFGAN, YILDIZ RAMAZAN, GEREDELI ÇAĞLAYAN, ÜNEK İLKAY TUĞBA, ÇOLAK D, KÜÇÜKÖNER MEHMET, ELKIRAN EMİN TAMER, HELVACI KAAN, DANE FAYSAL, BALAKAN OZAN, KAPLAN MUHAMMET ALİ, AYŞE DURNALI, HARPUTLUOĞLU HAKAN, GÖKSEL ÖZTÜRK GAMZE, ÖZDEMİR

18. Efficacy of Pemetrexed or Pemetrexed Plus Cisplatin/Carboplatin in Pretreated Patients with Advanced Non–Small Cell Lung Cancer. International Journal of Current Research and Review, 10(7), 22–27.

NAŞAR Nurgül, GEREDELI ÇAĞLAYAN

19. Predictive importance of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant therapy

GEREDELI ÇAĞLAYAN, ARICI SERDAR

20. The Impact of Ramadan I‘tikaf on the Immune System. Malaysian Journal of Public Health Medicine, 17(3), 104–108

EKER HASAN HÜSEYİN, ONUK MEHMET DERYA, GEREDELI ÇAĞLAYAN, ABUDULİ MAİHEBURETİ

21. Comparison of Somatostatin and Famotidine for the Treatment of Nonvariceal Acute Upper Gastrointestinal Bleeding. International Journal of Current Research and Review, 10(8), 25–27.

GEREDELI ÇAĞLAYAN

22. Effectiveness and tolerability of the FOLFIRINOX regimen in metastatic pancreatic cancer. The Medical Journal of Okmeydani Training and Research Hospital, 34(2)

GEREDELI ÇAĞLAYAN, Cihan Şener, YAŞAR Nurgül, SAKIN ABDULLAH, CAN ORÇUN, ARTAC MEHMET, KARAAĞAÇ MUSTAFA, KORAL LOKMAN

23. Does tumor localization of operated NSCLC affect relapse and survival? The Medical Journal of Okmeydani Training and Research Hospital, 34(2)

GEREDELI ÇAĞLAYAN

24. FOLFIRI plus panitumumab as first-line treatment in KRAS wild-type metastatic colorectal cancer: A single-center experience. The Medical Journal of Okmeydani Training and Research Hospital

GEREDELI ÇAĞLAYAN

25. Comparison of In-Hospital Cardiopulmonary Resuscitation Results Before and After the Introduction of Code Blue. Turkiye Klinikleri Journal of Anesthesiology and Reanimation, 13(2), 78–85

ÇİÇEKÇİ Faruk, SIZER Çiğdem, GEREDELI ÇAĞLAYAN, KARACA Halit, KARA FATİH, KARAİBRAHİMOĞLU ADNAN

26. The prevalence of BRCA1/BRCA2 mutations among women under age 60 with triple-negative breast cancer: A single-center experience. Erciyes Medical Genetics Days

GEREDELI ÇAĞLAYAN, Ertürk Biray

27. BRCA1 and BRCA2 Gene Mutation Rates in Turkish Breast Cancer Patients Under 40 Years Old: Single-Center Experience. 2nd Bursa Oncology Days

GEREDELI ÇAĞLAYAN

28. The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer

Dilek Çağlayan, Mehmet Zahid Koçak, Çağlayan Geredeli, Ali Murat Tatlı, Sema Sezgin Göksu, Melek Karakurt Eryılmaz, Murat Araz & Mehmet Artaç

29. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

Sabin Goktas Aydin, Burcin Cakan Demirel, Ahmet Bilici, Atakan Topcu, Musa Barış Aykan, Seda Kahraman, Ilgın Akbıyık, Muhammed Mustafa Atci, Omer Fatih Olmez, Arzu Yaren, Mehmet Ali Nahit Sendur, Caglayan Geredeli, Mesut Seker, Yuksel Urun, Nuri Karadurmus

30. Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

Hanny Al-Samkari, Caglayan Geredeli, Cagatay Arslan, Ippokratis Korantzis, Gamze Gokoz Dogu, Marina Nechaeva

31. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for first-line treatment of metastatic or recurrent cervical cancer

Ali Murat Tatli, Fatih Teker, Arif Hakan Onder, Fatih Kose, Caglayan Geredeli, Mustafa Karaagac, Muhammet Ali Kaplan, Mevlude Inanc

32. Real-world treatment outcomes from nationwide Onco-Colon Turkey registry in RAS wild-type patients treated with biologics as second-line therapy in mCRC Mahmut Emre Yildirim, Mustafa Karaca, Mehmet Artac, Irfan Cicin, Caglayan Geredeli, Ahmet Alacacioglu

33. The effect of BMI on outcomes of CDK 4/6 inhibitor therapy in HR-positive metastatic breast cancer patients.

Dilek Çağlayan, Mehmet Zahid Koçak, Caglayan Geredeli, Ali Murat Tatli, Melek Karakurt Eryılmaz, Sema Sezgin Göksu

34. The Relation Between Hemogram Parameters and Survival in Extensive-Stage Small Cell Lung Cancer

Sakin A., Sahin S., Yasar N., Demir C., Arici S., Geredeli C., Cihan S.

35. Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study

Muhammed Mustafa Atcı, Çağlayan Geredeli, Seval Ay, Abdullah Sakin, Biray Ertürk, Şaban Seçmeler

36. Clinicopathologic and Prognostic Differences Between Three Age Groups (Child/Adolescent, Young Adults, Adults) of Colorectal Cancer Patients: A Multicenter Study

Kaplan M.A., Ozaydin S., Yerlikaya H., Karaagac M., Gumus M., Cil T., Yalcintas Arslan Ü., Ozdemir N., Sakin A., Bilici M., Koca D., Uysal M., Dane F., Sever Ö.N., Seker M.M., Oruc Seker Z., Can M.F., Geredeli C., Aksoy A., Pilanci K.N., Ozturk Topcu T., Isikdogan A.

37. Mean platelet volume and platelet distribution width correlate with prognosis of early colon cancer

Aysegul Sakin, Suleyman Sahin, Abdullah Sakin, Fatih Karatas, Nilay Sengul Samanci, Nurgul Yasar, Serdar Arici, Cumhur Demir, Caglayan Geredeli, Okan Dikker, Sener Cihan

38. Can 68Ga-PSMA PET/CT–derived prostate-specific membrane antigen expression parameters predict PSA response to enzalutamide treatment?

Karyağar Savaş, Güven Osman, Karyağar Sevda Sağlampınar, Arici Serdar, Selvi Oğuzhan, Geredeli Çağlayan, Özü̈lker Filiz

39… Factors Affecting Disease-Free Survival in Operated Nonmetastatic...